Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use

British Journal of Dermatology

Volumn 141, Issue 3, 1999, Pages 424-429

  Mrowietz, Ulrich ^a   Christophers, E ^a   Altmeyer, P ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Fumaric acid esters; Psoriasis; Treatment guidelines

Indexed keywords

FUMADERM; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; HEADACHE; HUMAN; KERATINOCYTE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS;

CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FLUSHING; FUMARATES; HUMANS; KERATINOCYTES; LIVER; LYMPHOCYTE COUNT; PRACTICE GUIDELINES; PSORIASIS; T-LYMPHOCYTES;

EID: 0032858530     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.03034.x     Document Type: Article

References (23)

1. Schweckendick W, Heilung von Psoriasis. Med Monatschr 1959; 13: 103-4.
2. Altmeyer P, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
3. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters. Results of a prospective multicentre study. Br J Dermatol 1997; 138: 456-60.
4. De Jong P, Bezemer AC, Zomerdijk TPL et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-74.
5. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390-5.
6. Asadullah K, Schmid H, Friedrich M et al. Influence of monomethylfumarate on monocytic cytokine formation-explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997; 189: 623-30.
7. Höxtermann S, Nüchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-30.
8. Sebök B, Bonnekoh B, Geisel J, Mahrle G. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994; 270: 79-87.
9. Thio HB, Zomerdijk TPL, Oudshoorn C at al. Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Br J Dermatol 1994; 131; 856-61.
10. Sebök B, Bonnekoh B, Mahrle G. IL-I alpha-induced expression of ICAM 1 on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate. Int J Dermatol 1994; 33: 367-70.
11. Sebök B, Bonnekoh B, Vetter R et al. The antipsoriatic dimethylfumarate suppresses interferon-γ-induced ICAM-I and HLA-DR expression on hyperproliferative keratinocytes. Quantification by culture plate-directed APAAP-ELISA technique. Eur J Dermatol 1998; 8: 29-32.
12. Nibbering PH, Thio B, Zomerdijk TPL et al. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 1993; 101: 37-42.
13. Vandermeeren M, Janssens S, Boergers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-I, and ICAM-I expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.
14. Nieboer C, de Hoop D, Langendijk PNJ et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990; 181: 33-7.
15. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized, doubles-blind, placebo-controlled study. J Am Acad Dermatol 1990; 22: 311-12.
16. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side-effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
17. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 35-40.
18. Altmeyer P, Hartwig R, Matthes U. Das Wirkungs- und Sicherheitsprolil von Fumarsäureestern in der oralen Langzeittherapic bei schwerer therapieresistenter Psoriasis vulgaris. Hautarzt 1996; 47: 190-6.
19. Altmeyer P, Höxtermann S, Auer T. Verlaufsbeobachtungen der Lymphozytensubpopulationen bei Psoriasis-Patienten unter oraler Therapie mit Fumaraten. Akt Dermatol 1996; 22: 272-7.
20. Roodnat JI, Christiaans MHL, Nugteren-Huying WM et al. Akute Niereninsuflizienz bei der Behandlung der Psoriasis mit Fumarsäure-Estern. Schweiz Med Wschr 1989; 119: 826-30.
21. Dalhoff K, Faerber P, Arnholdt H et al. Akutes Nierenvensagen unter Psoriasistherapie mit Fumarsäurederivaten. Dtsch Med Wochenschr 1990; 115: 1014-17.
22. Stühlinger W, Innerebner M, Aberer W. Nephrotoxische Wirkung einer Therapic mit Fumarsäureestern bei Psoriasis. Dtsch Med Wschr 1990; 115: 1712-15.
23. Petres J, Kalkhoff KW, Baron D et al. Der Einlluß von Fumarsäur-emonoethylester auf die Nukleinsäure- und Proteinsynthese PHA-stimulierter menschlicher Lymphozyten. Arch Dermatol Res 1975; 251: 295-300.